Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 313-317

  Fujimoto, Nobukazu ^a   Gemba, Kenichi ^a   Asano, Michiko ^a   Wada, Sae ^a   Ono, Katsuichiro ^a   Ozaki, Shinji ^a   Kishimoto, Takumi ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

Author keywords

Asbestos; Mesothelin; Mesothelioma

Indexed keywords

ASBESTOS; MESOTHELIN; SOLUBLE MESOTHELIN RELATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN ASBESTOS PLEURISY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART FAILURE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA DISEASE; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA METASTASIS; SENSITIVITY AND SPECIFICITY; TUBERCULOUS PLEURISY;

EID: 77956195012     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000048     Document Type: Article

References (29)

1. Ohshima H: Five cases with mesothelioma living near a now-defunct asbestos cement plant in Amagasaki city. Mainichi Newspaper (in Japanese): p1, June 29, 2005.
2. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
3. Ray M and Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896, 2009.
4. Shi HZ, Liang QL, Jiang J, Qin XJ and Yang HB: Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 13: 518-527, 2008.
5. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J and Yang HB: Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 63: 35-41, 2008.
6. Aoe K, Hiraki A, Maeda T, et al: Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion. Chest 126: 1195-1197, 2004.
7. Rump A, Morikawa Y, Tanaka M, et al: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198, 2004.
8. Chang K, Pai LH, Pass H, et al: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16: 259-268, 1992.
9. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA 93: 136-140, 1996.
10. Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197, 2003.
11. Ordonez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27: 1031-1051, 2003.
12. Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536, 1999.
13. Frierson HF Jr, Moskaluk CA, Powell SM, et al: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34: 605-609, 2003.
14. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795, 2001.
15. Hornick JL, Lauwers GY and Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 29: 381-389, 2005.
16. Watanabe H, Okada G, Ohtsubo K, et al: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas and chronic pancreatitis. Pancreas 30: 349-354, 2005.
17. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942, 2004.
18. Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.
19. Cristaudo A, Foddis R, Vivaldi A, et al: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13: 5076-5081, 2007.
20. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M M and Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3: 1317-1324, 2008.
21. Scherpereel A, Grigoriu B, Conti M, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173: 1155-1160, 2006.
22. Pass HI, Wali A, Tang N, et al: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-272, 2008.
23. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14: 1-12, 1996.
24. Histological Typing of Lung and Pleural Tumors. World Health Organization, Geneva, 1999.
25. Mountain CF: Revisions in the International System for staging lung cancer. Chest 111: 1710-1717, 1997.
26. Kohyama N and Suzuki Y: Analysis of asbestos fibers in lung parenchyma, pleural plaques and mesothelioma tissues of North A American insulation workers. Ann NY Acad Sci 643: 27-52, 1991.
27. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 170: 691-715, 2004.
28. Raviglione MC and Luelmo F: Update on the global epidemiology of tuberculosis. Curr Issues Public Health 2: 192-197, 1996.
29. Hiraki A, Aoe K, Eda R, et al: Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest 125: 987-989, 2004.